5. Subsequent Events	6 Months Ended
Feb. 28, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 5 – Subsequent Events On February 7, 2019, the Company executed a Joint Venture Agreement with Wize Pharma, Inc. (“Wize Pharma”), pursuant to which the parties agreed to form a joint venture entity in Israel to jointly research, develop and administer cannabinoid formulations to treat ophthalmic conditions. In connection with the Joint Venture Agreement, Wize Pharma issued the Company 900,000 shares of common stock of Wize Pharma and the Company issued Wize Pharma 2,263,944 shares of its common stock to Wize Pharma Inc. The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no other such events that warrant disclosure or recognition in the financial statements.

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 855
-URI http://asc.fasb.org/topic&trid=2122774

Name:	us-gaap_SubsequentEventsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration